CN106343413A - 一种辅助降血糖、降血压、降血脂的保健食品 - Google Patents
一种辅助降血糖、降血压、降血脂的保健食品 Download PDFInfo
- Publication number
- CN106343413A CN106343413A CN201610725536.9A CN201610725536A CN106343413A CN 106343413 A CN106343413 A CN 106343413A CN 201610725536 A CN201610725536 A CN 201610725536A CN 106343413 A CN106343413 A CN 106343413A
- Authority
- CN
- China
- Prior art keywords
- health food
- blood
- salviae miltiorrhizae
- blood pressure
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 50
- 210000004369 blood Anatomy 0.000 title claims abstract description 44
- 239000008280 blood Substances 0.000 title claims abstract description 44
- 230000036772 blood pressure Effects 0.000 title claims abstract description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 4
- 239000008103 glucose Substances 0.000 title abstract description 4
- 230000009467 reduction Effects 0.000 title abstract description 3
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 241000180649 Panax notoginseng Species 0.000 claims description 31
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 31
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 241000208340 Araliaceae Species 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241001092040 Crataegus Species 0.000 abstract 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 3
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 3
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 3
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 3
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 3
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- 235000005473 carotenes Nutrition 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- -1 have heart tonifying Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- 206010011703 Cyanosis Diseases 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000157 blood function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种辅助降血糖、降血压、降血脂的保健食品，主要是由山楂、田七、丹参按5‑1:1：0.5‑3的配料比根据常规的制剂技术，可制成任何便于使用的保健食品剂型。本发明的优点：1、本发明的保健食品对心血管疾病患者有明显辅助治疗效果，使用方便。2、无毒副作用，可长期服用。3、本发明的保健食品配伍中山楂种植面广，山楂来源丰富，价格低，从而降低了保健食品的价格，便于推广应用，并给患者减轻经济负担。
Description
技术领域
本发明涉及一种保健食品，特别是涉及一种由山楂、三七和丹参制成的对心血管疾病患者有保健作用的保健食品。
背景技术
近年来，高血压、高血脂、高血糖、冠心病，代谢综合症、肿瘤等发病率越来越高，严重威胁人们的健康，许多人同时患有多种疾病，同时服用降脂降压降糖或其它药物，会给病人带来严重的心理压力和经济负担，特别是目前中药材缺乏，中药材价格上幅度很大，从而提高了药品和保健食品的价格，给患者带来了更大的经济负担。
发明内容
本发明的目的，是提供一种辅助降血糖、降血压、降血脂的保健食品，保健效果确切，主要成分之一的山楂价格低，原料丰富，从而降低了保健食品的成本，具有显著的经济和社会意义。
采用的技术方案是：
一种辅助降血糖、降血压、降血脂的保健食品主要是由山楂、三七、丹参按5-1:1：0.5-3的配料比根据常规的制剂技术，制成任何一种便于使用的保健食品剂型。
方解：
1、山楂主要功效：性味与归经：山楂酸、甘、微温。归脾、胃、肝经。具 消食健胃，行气散瘀，化浊降脂。用于肉食积滞，胃脘胀满，泻痢腹痛，淤血经闭，产后瘀阻，心腹刺痛，胸痹心痛，疝气疼痛，高脂血症。焦山楂消食导滞作用增强。用于肉食积滞，泻痢不爽。现代药理学研究证实，三楂含有三萜类和黄酮类成份，有强心、降血脂、降血压、防止动脉粥样硬化，还能增强心肌收缩力，增加心输出量，扩张冠状动脉，增加冠脉血流量，降低心肌的氧耗量即起到强心和预防心绞痛的作用。此外山楂中的总黄酮有扩血管和持久降压的作用，因此，常服可治疗高血压，高脂血症，动脉粥样硬化等心脑血管疾病 ，还具有利尿，镇静作用，抗癌和防癌作用。山楂中还含有一种叫牡荆素的化合物，不仅能阻断亚硝酸的合成，还可以抑制黄曲霉素的致癌作用。其次，有丰富的营养价值，100g果肉中vitc含量高达89g，钙含量高达85mg，胡萝卜素含量也相当可观，还有铁、蛋白质等多种营养成份， 营养成份排水果、蔬菜前列。
2、三七是五加科属植物，性味与归经：甘、微苦、温。归肝、胃经。用于散瘀止血，消肿定痛。用于咯血，吐血，衄血，便血，崩漏，外伤出血，胸腹刺痛，跌扑肿痛。从现代药理学角度分析，主要含6种皂甙和谷甾醇，胡萝卜素，黄酮类化合物，人参皂甙是人参的主要成份，对增强体力，改善心肌氧代谢，提高动物缺氧的耐受能力很有作用，谷甾醇，胡萝卜素能降低血脂，而黄酮类化合物是扩张冠状动脉，改善心肌供血，增强血管弹性的有效成份，归纳起来有以下几种功效:
①具有良好的活血化瘀降低血液粘滞度，改善冠状动脉血循环，扩张血管作用，常服不仅能对冠心病，心绞痛有显著疗效，而且有预防功效，无病者可以起预防冠心病，和滋补强身作用。②本发明的保健食品长期服用有显著的造血功能及调整免疫作用，有较强的抗疲劳，提高学习和记忆能力的作用。③有很强的止血和散血功能。④抗衰老，抗氧化作用。⑤抗肿瘤作用。⑥降血脂胆固醇作用。⑦保护肝脏作用，促进肝细胞再生作用。
3、丹参为唇形科植物丹参的干燥根和根茎，性味与归经：苦，微寒。归心，肝经。活血祛瘀，通经止痛，清心除烦，凉血消痹。用于胸痹心痛，脘腹胁痛，癥瘕积聚，热痹疼痛，心烦不眠，月经不调，痛经经闭，疮疡肿痛现代研究发现丹参中含有隐丹参酮，丹参酮Ⅰ、ⅡA、ⅡB[1，2]、Ⅴ、Ⅵ，，丹参酸A、B、C，等，功效：①能扩张冠状动脉，增加冠脉循环，减轻心肌缺血，梗死的临床症状和增强心脏功能，调整心律，并能扩张外周血管，改善微循环。②有抗凝、促进纤溶，抑制血小板聚集，抑制血栓形成。③能降血脂，抑制实验动物冠状动脉粥样斑块形成。④可抑制或减轻肝细胞变性，坏死及炎症反应，促进肝细胞再生，并有抗纤维化作用。⑤能提高机体的耐缺氧的能力，促进细胞修复能力，加速骨折的愈合，能促进红细胞及血红蛋白的生成，使网织红细胞增多。⑥对多种细菌及结核杆菌有抑制作用。⑦中抠镇静作用，此外还有增强免疫、降低血糖及抗肿瘤作用。
从方解中清楚看出本发明的保健食品对治疗心血管疾病患者具有显著的保健作用，从理论上看，选药科学，配伍恰当，保健和疗效确切。
临床应用试验：
1、病例选择 明确诊断为高血压病、糖尿病、高脂血症、冠心病、肥胖症、脂肪肝，或有胸闷、心悸，反复头昏头痛血压波动不稳未明确诊断高血压病者，或以上疾病的高危人群。
2、观察内容及疗效判断标准：服用本发明的保健食品1个月后观察，自觉症状逐渐减轻，各项检查指标逐渐恢复正常，3个月后自觉症状明显减轻，各项指标接近正常，服药半年后几乎全部恢复正常，无不良反应。
3、服用方法和服用量：
每次5-10g，每日三次吞服，长期服用,(有急性并发症者需及时到医院就医)。
4、临床应用 1、高血压病 26例患者，需长期服用 1-3种降压药才能控制血压计 ，许多病人曾在停药后血压控制不良，自服用本发明的保健食品后半月逐渐停用其它降压药，每3天监测血压，结果在服药1个月后23例血压降到正常，自觉症状消失，3例血压波动不稳，需继续同时服用降压药。26例均接受长期服用本发明的保健食品。2、高血脂 9例高血脂病人，其中3例中重度脂肪肝，在服用本发明的保健食品数月后血脂恢复正常，腹部脂肪明显减少，复查B超脂肪肝明显好转。3、血糖异常 12例2型糖尿病患者和其它疾病伴血糖异常者5例，在服用本发明的保健食品数月后大部分血糖控制在正常范围，自觉症状缓解，4例需要同时服用其它降糖药，但剂量减小。4、冠心病 11例明确诊断为冠心病者，其中4例经常出现胸闷，心前区不适等到症状，心电图有不同程度的ST-T改变，在服用本发明的保健食品数月后症状明显缓解，心电图无心肌缺血表现。5、降低血液粘滞度 绝大多数病人在服用本发明的保健食品数月后面色红润，3例典型病例，2例为 慢性阻塞性肺病病人，1例为支气管哮喘病人，平常呈轻度到中度紫绀 ，服用本发明的保健食品数月后双唇红润，紫绀消失，复发次数也明显减少，症状明显减轻。6、增强免疫 强壮身体素质，所有长期服用本发明的保健食品的病人，均觉身体状态较前明显好转，抵抗力增强，活力增加。
功效讨论
本发明的保健食品优点：
1、本发明的保健食品对心血管疾病患者有明显保健作用和治疗效果，使用方便。
2、无毒副作用，可长期服用。
3、本发明的保健食品配伍中山楂占比量大，山楂来源丰富，价格低，从而降低了保健食品的价格，便于推广应用，并给患者减轻经济负担。
具体实施方式
实施例一
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按1:1:1取料，即取山楂100g、三七100g、丹参100g加适量辅料，制成丸剂、胶囊、片剂或粉剂。
实施例二
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按2:1:2取料，即取山楂200g、三七100g、丹参200g加适量辅料制成片剂。
实施例三
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按3:1:2取料，即取山楂300g、三七100g、丹参200g加适量辅料制成颗粒剂。
实施例四
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按2:1:1取料，即取山楂200g、三七100g、丹参100g加适量辅料制成胶囊。
实施例五
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按3:1:3取料，即取山楂300g、三七100g、丹参300g加适量辅料制成粉剂。
实施例六
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按5:1:0.5取料，即取山楂500g、三七100g、丹参50g加适量辅料制成片剂。
实施例七
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按4:1:1取料，即取山楂400g、三七100g、丹参100g加适量辅料制成颗粒剂。
实施例八
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按5:1:3取料，即取山楂500g、三七100g、丹参300g加适量辅料制成胶囊。
实施例九
一种辅助降血糖、降血压、降血脂的保健食品，是由山楂、田七和丹参按4:1:2取料，即取山楂400g、三七100g、丹参200g加适量辅料制成粉剂。
Claims (10)
1.一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：主要是由山楂、三七、丹参按5-1:1:0.5-3的配料比制成丸剂、胶囊、颗粒、片剂或粉剂构成。
2.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为1:1:1。
3.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为2:1:2。
4.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为3:1:2。
5.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为2:1:1。
6.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为3:1:3。
7.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为5:1:0.5。
8.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为4:1:1。
9.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为5:1:3。
10.根据权利要求1所述的一种辅助降血糖、降血压、降血脂的保健食品，其特征在于：山楂、三七和丹参的配料比为4:1:2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610725536.9A CN106343413A (zh) | 2016-08-26 | 2016-08-26 | 一种辅助降血糖、降血压、降血脂的保健食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610725536.9A CN106343413A (zh) | 2016-08-26 | 2016-08-26 | 一种辅助降血糖、降血压、降血脂的保健食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106343413A true CN106343413A (zh) | 2017-01-25 |
Family
ID=57856060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610725536.9A Withdrawn CN106343413A (zh) | 2016-08-26 | 2016-08-26 | 一种辅助降血糖、降血压、降血脂的保健食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106343413A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619108A (zh) * | 2018-05-29 | 2018-10-09 | 云南永孜堂制药有限公司 | 参七心疏胶囊的应用及其制备方法 |
| CN112535281A (zh) * | 2019-09-23 | 2021-03-23 | 李济成 | 一种具有降血压降血糖功能的保健食品及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1785284A (zh) * | 2004-12-10 | 2006-06-14 | 天津天士力制药股份有限公司 | 一种含有何首乌的药物组合物 |
| CN101214049A (zh) * | 2007-12-26 | 2008-07-09 | 南方李锦记有限公司 | 一种具有辅助降血脂功能的保健食品 |
| CN103251700A (zh) * | 2012-05-18 | 2013-08-21 | 乔德京 | 丹参三七片 |
-
2016
- 2016-08-26 CN CN201610725536.9A patent/CN106343413A/zh not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1785284A (zh) * | 2004-12-10 | 2006-06-14 | 天津天士力制药股份有限公司 | 一种含有何首乌的药物组合物 |
| CN101214049A (zh) * | 2007-12-26 | 2008-07-09 | 南方李锦记有限公司 | 一种具有辅助降血脂功能的保健食品 |
| CN103251700A (zh) * | 2012-05-18 | 2013-08-21 | 乔德京 | 丹参三七片 |
Non-Patent Citations (2)
| Title |
|---|
| FAN84144410: "田七、山楂、丹参配伍防治多种心血管病", 《豆丁网》 * |
| QI17890319015: "田七、山楂、丹参配伍用于多种疾病的防治", 《豆丁网》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619108A (zh) * | 2018-05-29 | 2018-10-09 | 云南永孜堂制药有限公司 | 参七心疏胶囊的应用及其制备方法 |
| CN112535281A (zh) * | 2019-09-23 | 2021-03-23 | 李济成 | 一种具有降血压降血糖功能的保健食品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019101804A4 (en) | Traditional Chinese medicine medical nutrition therapy-based composition for treating diabetes, and application | |
| CN101695376B (zh) | 预防糖尿病的保健食品 | |
| CN102940801A (zh) | 一种治疗高血压的中药组合物 | |
| CN103169793B (zh) | 一种治疗三高症的药物 | |
| CN104757669B (zh) | 一种降压降脂保健饮料及其制备方法 | |
| CN106176953A (zh) | 一种包含青钱柳叶、罗汉果和桑叶的降血糖保健组合物 | |
| CN103637179B (zh) | 一种降血糖、降血脂和改善脂肪肝的食物组合物 | |
| CN106177183A (zh) | 一种包含青钱柳叶、绿茶和桑叶的降血糖保健组合物 | |
| CN104873705A (zh) | 一种治疗冠心病心绞痛的药物组合物及其应用 | |
| CN103479754B (zh) | 降压药及其制备方法 | |
| CN105079494A (zh) | 一种降血糖的铁皮石斛胶囊及其制备方法 | |
| CN106343413A (zh) | 一种辅助降血糖、降血压、降血脂的保健食品 | |
| CN106176952A (zh) | 一种包含青钱柳叶和苦丁茶的保健组合物 | |
| CN104645249B (zh) | 一种治疗冠心病心绞痛的药物 | |
| CN106490558A (zh) | 一种保健蜂蜜及其制备方法 | |
| CN102380032A (zh) | 一种治疗糖尿病性心脏病的中药 | |
| CN103977390A (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
| CN107320631A (zh) | 一种抗疲劳中药组合物及其制备方法 | |
| CN106822660A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
| CN104887759A (zh) | 一种人参粉酒及其制备方法 | |
| CN104324229A (zh) | 缓解疲劳的组合物及其制剂和应用 | |
| CN110150428A (zh) | 一种养生降糖茶及其制备方法 | |
| CN104799276B (zh) | 一种麻七利血溶栓粉及其制备方法 | |
| CN106728828A (zh) | 一种治疗冠心病的中药制剂及其制备工艺 | |
| CN101797330B (zh) | 调脂通络胶囊 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170125 |
|
| WW01 | Invention patent application withdrawn after publication |